|
1
|
Wu JT, Kakar S, Nelson RL, Mihalov ML,
Hayward B, Gilbert PB and Ghosh L: Prognostic significance of DCC
and p27Kip1 in colorectal cancer. Appl Immunohistochem Mol Morphol.
13:45–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Draht MX, Riedl RR, Niessen H, Carvalho B,
Meijer GA, Herman JG, van Engeland M, Melotte V and Smits KM:
Promoter CpG island methylation markers in colorectal cancer: The
road ahead. Epigenomics. 4:179–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wong BC, Wong WM, Cheung KL, Tong TS,
Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, et al: A
sensitive guaiac faecal occult blood test is less useful than an
immunochemical test for colorectal cancer screening in a Chinese
population. Aliment Pharmacol Ther. 18:941–946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quintero E, Castells A, Bujanda L,
Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD,
Hernández C, et al: Colonoscopy versus fecal immunochemical testing
in colorectal-cancer screening. N Engl J Med. 366:697–706. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park KS, Kim SJ, Kim KH and Kim JC:
Clinical characteristics of TIMP2, MMP2, and MMP9 gene
polymorphisms in colorectal cancer. J Gastroenterol Hepatol.
26:391–397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aguilera O, Fraga MF, Ballestar E, Paz MF,
Herranz M, Espada J, García JM, Muñoz A, Esteller M and
González-Sancho JM: Epigenetic inactivation of the Wnt antagonist
DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene.
25:4116–4121. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pauli A, Rinn JL and Schier AF: Non-coding
RNAs as regulators of embryogenesis. Nat Rev Genet. 12:136–149.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: MiR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vorvis C, Koutsioumpa M and Iliopoulos D:
Developments in miRNA gene signaling pathways in pancreatic cancer.
Future Oncol. 12:1135–1150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khamas A, Ishikawa T, Shimokawa K, Mogushi
K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara
K: Screening for epigenetically masked genes in colorectal cancer
Using 5-Aza-2′-deoxycytidine, microarray and gene expression
profile. Cancer Genomics Proteomics. 9:67–75. 2012.PubMed/NCBI
|
|
12
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ames BN and Gold LS: Too many rodent
carcinogens: Mitogenesis increases mutagenesis. Science.
249:970–971. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramel C: Short-term testing-are we looking
at wrong endpoints? Mut Res. 205:13–24. 1988. View Article : Google Scholar
|
|
15
|
Stanbridge EJ: Identifying tumor
suppressor genes in human colorectal cancer. Science. 247:12–13.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Preston-Martin S, Pike MC, Ross RK, Jones
PA and Henderson BE: Increased cell division as a cause of human
cancer. Cancer Res. 50:7415–7421. 1990.PubMed/NCBI
|
|
17
|
Williams GH and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martín-Romero FJ, Santiago-Josefat B,
Correa-Bordes J, Gutierrez-Merino C and Fernandez-Salguero P:
Potassium-induced apoptosis in rat cerebellar granule cells
involves cell-cycle blockade at the G1/S transition. J Mol
Neurosci. 15:155–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartkova J, Lukas J, Müller H, Lützhøt D,
Strauss M and Bartek J: Cyclin D1 protein expression and function
in human breast cancer. Int J Cancer. 57:353–361. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang W, Zhang YJ, Kahn SM, Hollstein MC,
Santella RM, Lu SH, Harris CC, Montesano R and Weinstein IB:
Altered expression of the cyclin D1 and retinoblastoma genes in
human esophageal cancer. Proc Natl Acad Sci USA. 90:9026–9030.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in cancer
therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng D, Tu Z, Wu W and Liang C: Inhibiting
the expression of DNA replication-initiation proteins induces
apoptosis in human cancer cells. Cancer Res. 63:7356–7364.
2003.PubMed/NCBI
|
|
24
|
Brunet A, Park J, Tran H, Hu LS, Hemmings
BA and Greenberg ME: Protein kinase SGK mediates survival signals
by phosphorylating the forkhead transcription factor FKHRL1
(FOXO3a). Mol Cell Biol. 21:952–965. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tangir J, Bonafé N, Gilmore-Hebert M,
Henegariu O and Chambers SK: SGK1, a potential regulator of c-fms
related breast cancer aggressiveness. Clin Exp Metastasis.
21:477–483. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yano F, Kugimiya F, Ohba S, Ikeda T,
Chikuda H, Ogasawara T, Ogata N, Takato T, Nakamura K, Kawaguchi H
and Chung UI: The canonical Wnt signaling pathway promotes
chondrocyte differentiation in a Sox9-dependent manner. Biochem
Biophys Res Commun. 333:1300–1308. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barrionuevo F and Scherer G: SOX E genes:
SOX9 and SOX8 in mammalian testis development. Int J Biochem Cell
Biol. 42:433–436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Darido C, Buchert M, Pannequin J, Bastide
P, Zalzali H, Mantamadiotis T, Bourgaux JF, Garambois V, Jay P,
Blache P, et al: Defective claudin-7 regulation by Tcf-4 and Sox-9
disrupts the polarity and increases the tumorigenicity of
colorectal cancer cells. Cancer Res. 68:4258–4268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Passeron T, Valencia JC, Bertolotto C,
Hoashi T, Le Pape E, Takahashi K, Ballotti R and Hearing VJ: SOX9
is a key player in ultraviolet B-induced melanocyte differentiation
and pigmentation. Proc Natl Acad Sci USA. 104:13984–13989. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Leav I, Ibaragi S, Wegner M, Hu
GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal
prostate epithelium and enhances prostate cancer invasion. Cancer
Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E,
Huang Q and Lai M: Analysis of SOX9 expression in colorectal
cancer. Am J Clin Pathol. 130:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu X, Yang W and Wu X: Expression of SOX9
and CDX2 in Colorectal Cancer. Chin J Surg Int Trad Western Med.
17:564–567. 2011.(In Chinese).
|
|
33
|
Schouten M, Fratantoni SA, Hubens CJ,
Piersma SR, Pham TV, Bielefeld P, Voskuyl RA, Lucassen PJ, Jimenez
CR and Fitzsimons CP: MicroRNA-124 and −137 cooperativity controls
caspase-3 activity through BCL2L13 in hippocampal neural stem
cells. Sci Rep. 5:124482015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato K and Akimoto K: Expression levels of
KMT2C and SLC20A1 identified by information-theoretical analysis
are powerful prognostic biomarkers in estrogen receptor-positive
breast cancer. Clin Br Cancer. 17:e135–e142. 2017. View Article : Google Scholar
|
|
35
|
Wiesmann F, Veeck J, Galm O, Hartmann A,
Esteller M, Knüchel R and Dahl E: Frequent loss of endothelin-3
(EDN3) expression due to epigenetic inactivation in human breast
cancer. Breast Cancer Res. 11:R342009. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Chen L, Wu Z, Wang M, Jin F, Wang
N, Hu X, Liu Z, Zhang CY, Zen K, et al: miR-124-3p functions as a
tumor suppressor in breast cancer by targeting CBL. BMC Cancer.
16:8262016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng D, Wang L, Chen Y, Li B, Xue L, Shao
N, Wang Q, Xia X, Yang Y and Zhi F: MicroRNA-124-3p regulates cell
proliferation, invasion, apoptosis, and bioenergetics by targeting
PIM1 in astrocytoma. Cancer Sci. 107:899–907. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao H, Dong T, Zhou H, Wang L, Huang A,
Feng B, Quan Y, Jin R, Zhang W, Sun J, et al: miR-320a suppresses
colorectal cancer progression by targeting Rac1. Carcinogenesis.
35:886–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li JM, Zhao RH, Li ST, Xie CX, Jiang HH,
Ding WJ, Du P, Chen W, Yang M and Cui L: Down-regulation of fecal
miR-143 and miR-145 as potential markers for colorectal cancer.
Saudi Med J. 33:24–29. 2012.PubMed/NCBI
|
|
41
|
Wu H, Xiao Z, Wang K, Liu W and Hao Q:
MiR-145 is downregulated in human ovarian cancer and modulates cell
growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys
Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xing AY, Wang B, Shi DB, Zhang XF, Gao C,
He XQ, Liu WJ and Gao P: Deregulated expression of miR-145 in
manifold human cancer cells. Exp Mol Pathol. 95:91–97. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thuringer D, Jego G, Berthenet K, Hammann
A, Solary E and Garrido C: Gap junction-mediated transfer of
miR-145-5p from microvascular endothelial cells to colon cancer
cells inhibits angiogenesis. Oncotarget. 7:28160–28168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li CY, Xiong DD, Huang CQ, He RQ, Liang
HW, Pan DH, Wang HL, Wang YW, Zhu HW and Chen G: Clinical value of
miR-101-3p and biological analysis of its prospective targets in
breast cancer: A study based on the cancer genome atlas (TCGA) and
bioinformatics. Med Sci Monit. 23:1857–1871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H
and Cai J: MiR-186-5p upregulation inhibits proliferation,
metastasis and epithelial-to-mesenchymal transition of colorectal
cancer cell by targeting ZEB1. Arch Biochem Biophys. 640:53–60.
2018. View Article : Google Scholar : PubMed/NCBI
|
